Luveltamab tazevibulin,Pegfilgrastim
Sutro Biopharma,Amgen
['pivotal study', 'pivot,io,i', 'ovarian', 'sutro', '$stro']
$stro sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal study reframe-o1 
News and analysis of biomedical, biopharma, biotech, biosciences, pharmaceutical, and technology equities